Job Placement · Biotech and Life Sciences · Director of Clinical / Regulatory
Biotech director of clinical/regulatory placement on milestone billing, not contingency. Directors own the clinical development plan or regulatory strategy across a program, priced by BLS's natural sciences manager code at a 167,220 median, though candidates with matching FDA pathway experience sit at 221,540 to 316,850. BEG fills the seat in 23 to 35 days from 19,080.
See your exact placement price - no call required
See pricing before you talk to anyone. No demo gate, no obligation, and no co-employment.
TL;DR
A director of clinical/regulatory is the name on a program's FDA submissions, plural, across every study underneath it, not the single submission a manager signs or the section a specialist drafts. BLS prices the home code, natural sciences managers, at a 167,220 median, but directors with matching FDA pathway experience across CDER or CBER sit at 221,540 to 316,850. BEG prices the search from 19,080.
Why This Search Stalls
Boards want a director who has taken a product through the same FDA center and phase in the same modality, but those candidates sit at the 221,540 to 316,850 upper range or hold unvested equity a cash offer at the 167,220 median cannot match.
How BEG Fills This Seat
BEG scopes the seat to program-wide ownership rather than one study, sources for a matching FDA center and modality history, and pushes the equity number to a decision before the finalist is named.
| Step | What it requires | Where it stalls |
|---|---|---|
| Scope the program-wide mandate | A job description for the clinical development plan or regulatory strategy across a program’s studies, agency interactions, and the managers and vendors who execute it | Boards write the role like a manager job with a director title, then cannot explain why candidates ask about portfolio scope |
| Source for FDA-center and modality match | A director who has taken a product through the same FDA center and phase, in the same modality, the lead program is entering | That exact match is priced at the 221,540 to 316,850 upper range, not the 167,220 median the posting is written against |
| Resolve the equity question before the offer | A board decision on how much equity a director candidate gets, made before the finalist is named | Boards decline to set the equity number until someone is named, so a cash offer at the median cannot buy out equity the finalist holds elsewhere |
| Close against the direct-report pipeline | An understanding of what the director’s direct reports, medical scientists at a 103,410 median, cost to retain and grow | A director hired without budget authority over that reporting line inherits a team priced below market and starts the job already behind |
CDER approved 46 novel drugs in 2025 and CBER lists 54 licensed cell and gene therapy products, and which center a director has actually filed submissions with, not just which studies they managed, is what BEG screens for before a program-wide candidate is presented.
Milestone Billing Against Contingency
Tier IV is fixed at 19,080 to 22,896 no matter how many studies or submissions sit under the program, which is the point: a director's scope does not shrink to fit a narrower search the way a contingency percentage would shrink with a lower base. The natural sciences manager code spans federal government at a 141,300 median and state government at 105,470, well below research and development's 209,060, so a submission history built at a university or agency prices very differently than one built inside a sponsor.
The Director of Clinical/Regulatory Math
The number that actually matters for this search is not in this arithmetic at all: BLS's wage tables exclude stock options, and the finalist a board wants has usually already vested equity in a program that has not read out. What the tables do show is that BEG's fee holds regardless, Tier IV at 19,080 to 22,896, 57 to 68 percent of the 33,444 a 20 percent contingency recruiter would bill against the 167,220 natural sciences manager median (BLS), and 46 to 55 percent against the 209,060 research and development median where most of these searches are actually benchmarked. Contingency pricing only gets more expensive as a board tries to buy out that equity with a higher base; BEG's fee does not move. BEG is cheaper than contingency at every wage point cited for this role.
Contingency, BEG, or Temp
A contingency fee scales with a six-figure base; BEG's fixed Tier IV fee runs 32 to 55 percent below a 20 percent contingency fee depending on the benchmark, and holds regardless of the equity negotiation.
| Model | Who employs | How you pay | Right when |
|---|---|---|---|
| Contingency recruiter | You, direct | First-year salary times 20 to 25 percent, a recruiter’s standard cut, due at start | A director search where a fee tied to a six-figure base is acceptable |
| BEG milestone placement | You, direct hire | Tier IV, fixed at 19,080 to 22,896, staged across the search rather than billed all at once | A portfolio-level hire where BEG runs 32 to 55 percent below a 20 percent contingency fee depending on benchmark |
| Staffing or temp agency | The agency, not you | Hourly billing plus markup, for however long the assignment continues | Interim program leadership during a transition, not a permanent director hire |
A director's fee reflects program-wide submission ownership, several studies deep, not a single product's release signature. See every tier and role BEG places across the vertical on the hub.
FAQ
The director owns the clinical development plan or regulatory strategy across a program’s studies and submissions, the agency interactions, the CRO or vendor contracts, and the managers who run them, reporting to a VP. A manager who owns one study or one submission does not carry that program-wide scope.
Boards want a director who has taken a product through the same FDA center and phase in the same modality, and that experience is priced at the 221,540 to 316,850 upper range or held by someone with unvested equity. Boards often will not set the new hire’s equity number until a finalist is named, so a cash offer at the median cannot close the gap.
BLS prices the natural sciences manager code directors are counted under at a 167,220 median, with the middle half running 119,430 to 221,540 and the top decile above 316,850. By employer type, federal government pays a 141,300 median and state government 105,470, well below the 209,060 research and development figure most biotech director searches are actually benchmarked against.
Yes, across the full scope of the role. A single-study comparison would understate it: BEG’s Tier IV fee runs 57 to 68 percent of a 20 percent contingency fee at the 167,220 national median, and the gap only grows at the 209,060 research and development median, where BEG runs 46 to 55 percent, the industry median most program-wide submission histories are actually built in.
This program-wide seat carries BEG’s Tier IV milestone fee, 19,080 to 22,896, the same range as a medical affairs director because both draw on the same natural sciences manager code. Unlike a contingency percentage, it holds regardless of how the equity portion of the offer is structured.
No. BEG places directors of clinical/regulatory as your direct, permanent employees on milestone billing, not as interim or agency-employed staff.
23 to 35 days is the average here too, with an 86 percent fill rate, though sourcing a full submission history under one FDA pathway usually sets the pace, not the search process itself.
BLS lists a bachelor’s degree in a science field plus five years or more as a scientist as typical entry, with some employers requiring a master’s or Ph.D. The seat sets research goals, budgets staffing and equipment, hires and evaluates the scientists and technicians who report in, and coordinates testing, quality control and production; O*NET lists clinical research coordinators under this same code.
Medical scientists, the director’s typical direct reports, earn a 103,410 median and are projected to grow 13 percent through 2035 with about 10,500 openings a year, so retaining that team is itself a competitive hiring problem.
Whether a candidate has taken a program through CDER, which approved 46 novel drugs in 2025, or CBER, which lists 54 licensed cellular and gene therapy products, defines whether their filing history matches the lead program’s modality.
BLS notes that total executive compensation often includes stock options and bonuses beyond salary, and OEWS wage data exclude the self-employed, so no published figure shows what a candidate’s unvested equity elsewhere is actually worth against a new cash offer.
A manager owns one product’s quality system or regulatory strategy. A director owns a program’s studies and submissions across several managers. A VP owns the portfolio, budget and headcount plan across several directors, one level higher than this seat.
Compare this seat with the QA / regulatory manager role below it, or the VP of R&D / clinical seat above it. Every biotech role BEG places is on the Biotech and Life Sciences hub.
More Biotech and Life Sciences placement
Ready?
Answer a few questions, get your exact number in about 90 seconds. No call required, no commitment.
See your exact placement price - no call required
